NDAINJECTIONINJECTABLE
Approved
Oct 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURABOLIN (nandrolone phenpropionate) is an injectable anabolic steroid approved by the FDA in 1959. It is a synthetic derivative of testosterone used historically for protein anabolism and treatment of certain anemias and wasting conditions. The drug functions as an androgen receptor agonist to promote muscle protein synthesis and red blood cell production.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), indicating a mature legacy product with limited growth opportunities and likely smaller brand support teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DURABOLIN represents a legacy product with limited career growth trajectory and zero linked job openings currently available. Working on this product would involve managing a mature portfolio asset through its end-of-life phase rather than driving innovation or significant commercial expansion.
Brand ManagerMedical Science Liaison
Worked on DURABOLIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.